Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PGNY with free AI briefings, catalyst countdowns, and dilution alerts.

PGNY · Progyny, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$195.6M Cash on Hand
CF+ Cash Runway
Follow PGNY by email Get an email when PGNY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PGNY, unsubscribe in one click. Privacy

📣 What PGNY Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

💰 Cash Runway & Dilution Risk

PGNY holds $195.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PGNY files for a raise →

👥 Who Owns PGNY

Insiders 2% Institutions (438 holders) 98% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 11,294,526 15.34% 2026-09-30
FMR LLC Institution (13G, 5%+) 7,004,280 9.51% 2026-06-30
Vanguard Portfolio Management Institution (13G, 5%+) 5,357,311 7.27% 2026-03-31
Peter Anevski
CHIEF EXECUTIVE OFFICER, Director · +389,380 options
Insider 710,972 0.97% 2026-11-10
David J Schlanger
Executive Chairman, Director · +32,229 options
Insider 238,462 0.32% 2026-11-10
Norman Payson
Director · +27,119 options
Insider 134,842 0.18% 2026-05-21
Allison Swartz
EVP, GC · +52,800 options
Insider 83,976 0.11% 2026-11-02
Mark S. Livingston
CHIEF FINANCIAL OFFICER · +66,289 options
Insider 70,314 0.10% 2026-11-04
Melissa B Cummings
Chief Operating Officer · +66,289 options
Insider 66,496 0.09% 2026-10-14
Geoffrey Clapp
Chief Product Officer · +77,584 options
Insider 58,235 0.08% 2026-11-11
Jeffrey G Park
Director · +31,458 options
Insider 39,981 0.05% 2026-05-21
Roger C Holstein
Director · +29,289 options
Insider 28,729 0.04% 2026-05-21

Share count 73,647,334 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PGNY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PGNY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.